Prescription medicine
Amoxicillin and clarithromycin and vonoprazan Brand names: Voquezna; first approved as Voquezna Triple
Amoxicillin and clarithromycin and vonoprazan (Voquezna) is a prescription medicine with an FDA approval on record since 2022. No generic is listed; pharmacies paid $7.52 per unit (Voquezna triple pak) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: amoxicillin and clarithromycin and vonoprazan labels on DailyMed; the NDA 215152 record on Drugs@FDA; every amoxicillin and clarithromycin and vonoprazan label on DailyMed.
Highlights of the record
no current FDA label; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
The label in openFDA carries no indications section.
Forms and strengths
Kit.
On the market
- Earliest approval on file
- May 3, 2022 Voquezna Triple Pak, Phathom; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- August 11, 2030 Voquezna Triple Pak capsules; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $7.52 per unit Voquezna triple pak
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 41 through July 30, 2026
Is there a generic for amoxicillin and clarithromycin and vonoprazan (Voquezna)?
No generic amoxicillin and clarithromycin and vonoprazan is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Voquezna Triple Pak capsules: the compound patent runs to April 10, 2030, and the last listed entry to August 11, 2030. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2022 earliest approval on file
- 2030 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for amoxicillin and clarithromycin and vonoprazan (Voquezna)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $7.52 per unit (Voquezna triple pak), up 3% from $7.27 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Voquezna triple pak (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Voquezna triple pak | Brand | $7.52 per unit | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for amoxicillin and clarithromycin and vonoprazan?
The FDA Adverse Event Reporting System holds 41 reports that list amoxicillin and clarithromycin and vonoprazan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 3 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Amoxicillin and clarithromycin and vonoprazan side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other